Amrutanjan Health Care Limited (AMRUTANJAN) fair value: what the stock is really worth
As of Nov 11, 2026: fair value (intrinsic value) of Amrutanjan Health Care Limited stock ₹374, price ₹521, that is 28.2% below the price, quality 56 out of 100. Rating: overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range ₹485.38 – ₹958.10 · fair‑value band ₹261.84 – ₹486.28 · the ₹520.75 price screens above the ₹374.06 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.
Follow Amrutanjan Health Care in your weekly email
Every Wednesday you see whether Amrutanjan Health Care is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Amrutanjan Health Care Limited manufactures, supplies, and sells ayurvedic pain balms and women hygiene products in India and internationally. It operates through OTC Products, Beverages, Women's Hygiene, and Others segments.
Show moreShow less
The company provides pain management products comprising pain balms and roll-ons, back pain roll-ons, stick-on patch, and joint muscle sprays; dental pain gel; and decorn corn caps; hand sanitizer under the NOGerms brand name; and fruit and rehydration juice drinks under the Fruitnik brand name.
The company also offers congestion management products that consists of cold rubs, cough syrups, nasal inhalers, and swas mints, as well as provides sanitary napkins for women. In addition, it operates a pain management center.
The company was formerly known as Amrutanjan Limited and changed its name to Amrutanjan Health Care Limited in 2007. Amrutanjan Health Care Limited was founded in 1893 and is based in Chennai, India.
Stock analysis
Amrutanjan Health Care Limited (AMRUTANJAN) currently trades at ₹520.75, while our model-based Fair Value estimate is ₹374.06, 28% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹398.25 per share, and 2 of the 16 models we run sit above the ₹520.75 price.
Bear case: the Asset-Based group reads lowest at ₹52.94, and 14 of the 16 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹261.84 (bear) to ₹486.28 (bull), the price of ₹520.75 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Amrutanjan Health Care Limited reported revenue of ₹5.0B in FY2026 versus ₹4.1B in FY2022, a compound +5.5%/yr. Reported net income was ₹579M in FY2026, compounding −3.6%/yr from FY2022.
Key figures
Market cap ₹15.1B (≈ $161M) Micro · P/E ratio 27.9 · P/S ratio 2.94 · EPS (TTM) ₹18.67 · Dividend yield 0.9% · Net margin 10.6% · Return on equity 16.6% · Return on assets (EBIT) 14.8% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (medium confidence).
What moves the price
The share trades about 27% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −28% fair-value upside, at −28%, AMRUTANJAN screens richer than that median.
Fair Value models
Bear₹261.84Fair Value ₹374.06Bull₹486.28
Price ₹520.75 · Downside -28.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹8.71 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.56/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+11.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.7%
Start year 2021 (pandemic). Over 10 years: +10.4% a year
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
0.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year−0.9%
Dividend (yield on the price)0.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−0.9% vs 11.0%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 14%
Compare Amrutanjan Health Care Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 607 stocks
Beats the industry median on 5/12 measures
A mixed picture versus its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside−28.2% · Below median
Profitability
Return on equity (12 months)16.6% · Top 25%
Return on assets11.4% · Top 25%
Net margin (12 months)10.6% · Above median
Operating margin (12 months)2.2% · Below median
Growth and dividend
Revenue growth (quarter YoY)9.5% · Above median
Dividend yield (12 months)0.9% · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/E (12 months)27.9× · Pricier than median
P/B4.07× · Priciest 25%
P/S (12 months)2.94× · Pricier than median
EV/EBITDA23.1× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 18
FUTURE (revenue growth)48· sector 25
PAST (return on equity)66· sector 25
HEALTH (low debt)0· sector 96
DIVIDEND (yield)18· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Amrutanjan Health Care Limited Fair Value". https://www.fairvalue-calculator.com/stock/AMRUTANJAN
Frequently asked questions
Is Amrutanjan Health Care Limited (AMRUTANJAN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of ₹374.06 versus a price of ₹520.75, about 28% lower (overvalued).
What is the fair value of AMRUTANJAN?
Our model-based fair value for Amrutanjan Health Care Limited is ₹374.06 (as of Nov 8, 2026), built from audited fundamentals. The current price: ₹520.75.
What is the quality score of AMRUTANJAN?
Amrutanjan Health Care Limited has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amrutanjan Health Care Limited (AMRUTANJAN)?
Our model-based price target is the fair value of ₹374.06 (as of Nov 8, 2026) from 16 valuation models. Cautious scenario ₹261.84, optimistic scenario ₹486.28. It is a calculation from audited fundamentals, not an analyst target.
What is the Amrutanjan Health Care Limited stock forecast for 2026?
Our models put fair value at ₹374.06, about 28% lower versus a price of ₹520.75 (overvalued). Cautious scenario ₹261.84, optimistic scenario ₹486.28. The calculation is refreshed regularly with new filings.
What is the revenue of Amrutanjan Health Care Limited (AMRUTANJAN)?
Amrutanjan Health Care Limited reported trailing-twelve-month revenue of about ₹5.1B (latest available figure, as of Nov 8, 2026).
Does Amrutanjan Health Care Limited pay a dividend?
Amrutanjan Health Care Limited currently shows a dividend yield of 0.88% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Amrutanjan Health Care Limited (AMRUTANJAN) and when is the ex-dividend date?
Amrutanjan Health Care Limited pays a dividend of ₹4.60 per share a year, a dividend yield of 0.9%. The last ex-dividend date was Nov 6, 2026. A dividend has been paid every year since at least 2010. The payout ratio is 24.6% of earnings. Our assessment: Token dividend. At a yield of 0.9% the dividend is symbolic. On paper it is not fully covered by earnings or free cash flow, but at this size that hardly matters: even scrapping it entirely would cost less than 0.9% a year, and coverage ratios on amounts this small swing with ordinary working-capital movements. Judge this company on its business, not on its dividend.
What is the intrinsic value of Amrutanjan Health Care Limited (AMRUTANJAN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amrutanjan Health Care Limited it is ₹374.06 per share (as of Nov 8, 2026), against a price of ₹520.75. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Amrutanjan Health Care Limited stock overvalued or undervalued in 2026?
As of Nov 8, 2026, AMRUTANJAN trades above its calculated fair value: price ₹520.75, fair value ₹374.06, a gap of about −28% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AMRUTANJAN?
No. The price is what the market pays today (₹520.75); the fair value is what the company's own numbers justify (₹374.06). For Amrutanjan Health Care Limited the two are ₹146.69 per share apart. That gap is exactly why we show both numbers side by side.
How much is Amrutanjan Health Care Limited worth?
The market values Amrutanjan Health Care Limited at about ₹15.1B (market capitalisation, as of Nov 8, 2026). Per share that is ₹520.75; our models calculate a fair value of ₹374.06 per share.
What do the bullish and bearish scenarios say about AMRUTANJAN?
Our models span a range for Amrutanjan Health Care Limited: cautious scenario ₹261.84, base ₹374.06, optimistic ₹486.28 per share (as of Nov 8, 2026, price ₹520.75). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of AMRUTANJAN?
Amrutanjan Health Care Limited trades at a price-to-earnings ratio of 27.9 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹374.06 is built from several models across several years. Median P/E at fiscal year-end, 8 fiscal years (2019 to 2026), reported earnings: 36.9. Other multiples: P/B 4.1, P/S 2.9, EV/EBITDA 23.1.
How solid is the balance sheet of Amrutanjan Health Care Limited (AMRUTANJAN)?
Balance-sheet figures for Amrutanjan Health Care Limited (as of Nov 8, 2026): return on equity 16.6%. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is AMRUTANJAN from its 52-week high?
Amrutanjan Health Care Limited trades at ₹520.75, about 27% below its 52-week high of ₹715.91 and 7% above the low of ₹485.38 (as of Nov 11, 2026). Distance from the high says nothing about value: that is what the fair value of ₹374.06 is for.
Which stocks are comparable to Amrutanjan Health Care Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amrutanjan Health Care Limited stock attractive at the current price?
The data as of Nov 8, 2026: price ₹520.75, calculated fair value ₹374.06 (−28%), Quality Score 56/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AMRUTANJAN calculated?
We run Amrutanjan Health Care Limited through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹374.06 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Amrutanjan Health Care Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Amrutanjan Health Care Limited (AMRUTANJAN)?
The closing price on Nov 11, 2026 was ₹520.75. Our model-based fair value is ₹374.06, about 28% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Amrutanjan Health Care Limited right now?
The price sits above even our optimistic bull case (₹486.28). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (₹261.84 to ₹486.28) leaves room in how you read the outcome.
Where does the earnings growth of Amrutanjan Health Care Limited (AMRUTANJAN) come from?
Earnings per share at Amrutanjan Health Care Limited grew +11.7 % a year from 2015 to 2026. Broken into its drivers: revenue per share +10.3 %, EBIT margin −2.4 %, tax rate +1.7 %, residual (interest, one-offs) +2.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Amrutanjan Health Care Limited
How large is the market capitalisation of Amrutanjan Health Care Limited (AMRUTANJAN)?
The market capitalisation of Amrutanjan Health Care Limited is ₹15.1B (≈ $161M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Amrutanjan Health Care Limited (AMRUTANJAN)?
The price-to-sales ratio of Amrutanjan Health Care Limited is 2.94 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Amrutanjan Health Care Limited (AMRUTANJAN)?
Earnings per share at Amrutanjan Health Care Limited are ₹18.67 (price ÷ EPS = P/E 27.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Amrutanjan Health Care Limited (AMRUTANJAN)?
The dividend yield of Amrutanjan Health Care Limited is 0.9% (payout 24.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Amrutanjan Health Care Limited (AMRUTANJAN)?
The net margin of Amrutanjan Health Care Limited is 10.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Amrutanjan Health Care Limited (AMRUTANJAN)?
The return on equity (ROE) of Amrutanjan Health Care Limited is 16.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Amrutanjan Health Care Limited (AMRUTANJAN)?
On an EBIT basis the return on assets of Amrutanjan Health Care Limited is 14.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Amrutanjan Health Care Limited (AMRUTANJAN)?
The operating margin of Amrutanjan Health Care Limited is 2.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Amrutanjan Health Care Limited (AMRUTANJAN)?
Revenue at Amrutanjan Health Care Limited is growing +9.5% versus a year earlier (3y avg +9.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Amrutanjan Health Care Limited (AMRUTANJAN)?
Earnings per share at Amrutanjan Health Care Limited are growing −47.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Amrutanjan Health Care Limited (AMRUTANJAN) generate?
The free cash flow of Amrutanjan Health Care Limited is −₹31.2M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Amrutanjan Health Care Limited (AMRUTANJAN) hold?
Amrutanjan Health Care Limited holds more cash than debt, ₹315M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Amrutanjan Health Care Limited in the live analysis
One click puts Amrutanjan Health Care Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026